We and others have shown that ATF3 is capable of binding to the NOXA promoter in other tumor contexts (e.g., squamous cell carcinoma of the head and neck) after other exposures, such as cisplatin (52, 53). Here, ATF3 is linked to squamous cell carcinoma.